On Aug. 11, 2005, the Food and Drug Administration (FDA) approved an application of a pediatric/adolescent formulation of VAQTA^® (hepatitis A vaccine, inactivated) (Merck) for use among persons aged 12 months–18 years.

The formulation, dosage, and schedule for VAQTA did not changed. Each 0.5 mL dose of the pediatric/adolescent formulation of VAQTA contained approximately 25 units of formalin-inactivated hepatitis A virus antigen, adsorbed onto aluminum hydroxyphosphate sulfate, in 0.9% sodium chloride. The formulation did not contain a preservative.